{"id":137,"date":"2023-09-15T09:05:38","date_gmt":"2023-09-15T07:05:38","guid":{"rendered":"https:\/\/web.penta-pco.com\/hdio-2023\/?page_id=137"},"modified":"2023-11-05T22:39:48","modified_gmt":"2023-11-05T21:39:48","slug":"program","status":"publish","type":"page","link":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/program\/","title":{"rendered":"Programme"},"content":{"rendered":"<p>Download the congress program <a href=\"https:\/\/web.penta-pco.com\/hdio-2023\/wp-content\/uploads\/2023\/11\/HDIO-2023-program-WEB.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a><\/p>\n\n\n\n<div class=\"wp-block-gutena-tabs gutena-tabs-block gutena-tabs-block-50779d-2c\"><ul class=\"gutena-tabs-tab tab-flex\"><li class=\"gutena-tab-title active\" data-tab=\"1\"><div class=\"gutena-tab-title-content icon-top\"><div class=\"gutena-tab-title-text\"><div>\u010cETVRTAK 9.11.<\/div><\/div><\/div><\/li><li class=\"gutena-tab-title inactive\" data-tab=\"2\"><div class=\"gutena-tab-title-content icon-top\"><div class=\"gutena-tab-title-text\"><div>PETAK 10.11.<\/div><\/div><\/div><\/li><li class=\"gutena-tab-title inactive\" data-tab=\"3\"><div class=\"gutena-tab-title-content icon-top\"><div class=\"gutena-tab-title-text\"><div>SUBOTA 11.11.<\/div><\/div><\/div><\/li><li class=\"gutena-tab-title inactive\" data-tab=\"4\"><div class=\"gutena-tab-title-content icon-top\"><div class=\"gutena-tab-title-text\"><div>NEDJELJA 12.11.<\/div><\/div><\/div><\/li><\/ul><div class=\"gutena-tabs-content is-layout-flow wp-block-gutena-tabs-is-layout-flow\">\n<div class=\"wp-block-gutena-tab gutena-tab-block gutena-tab-block-3f17b3-4d active\" data-tab=\"1\">\n<h2 class=\"wp-block-heading has-medium-font-size\"><\/h2>\n\n\n\n<figure class=\"wp-block-flexible-table-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td style=\"width:160px;background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong><strong>DVORANA A (HALL A<\/strong><\/strong><\/strong>)<\/td><\/tr><tr><td>15:00 &#8211; 15:10<\/td><td><strong>OTVARANJE KONGRESA <\/strong><br><strong>(CONGRESS OPENING<\/strong>)<\/td><\/tr><tr><td style=\"width:160px\">15:10 &#8211; 15:30<\/td><td><strong>Mario \u0160ekerija<br><\/strong>Epidemiologija raka u Hrvatskoj \u2013 gdje smo i kuda idemo? <br>(Cancer epidemiology in Croatia &#8211; where are we and where are we going?)<\/td><\/tr><tr><td style=\"width:160px\">15:30 &#8211; 16:00<\/td><td><strong>Anu\u0161ka Budisavljevi\u0107, Renata Kelemeni\u0107<br><\/strong>Ishodi lije\u010denja i organizacija onkolo\u0161ke skrbi, komparacija Hrvatske i zemalja u okru\u017eenju<br>(Treatment outcomes and organization of oncology care, comparison of Croatia and neighboring countries)<\/td><\/tr><tr><td>16:00 \u2013 16:45<\/td><td><strong>PANEL RASPRAVA<\/strong><br>Jesmo li na tragu smanjenja smrtnosti od zlo\u0107udnih bolesti i pobolj\u0161anja ishoda lije\u010denja \u2013 kojih i kako \u0107emo ih pratiti? <br>(Are we on track to reduce mortality from malignant diseases and improve treatment outcomes &#8211; which ones and how will we monitor them?)<br><br>(Predstavnici stru\u010dnih dru\u0161tava HR i SLO, MiZ, HZJZ, HZZO, udruge bolesnika) <br>(Representatives of professional societies of HR and SLO, MiZ, HZJZ, HZZO, patient association)<\/td><\/tr><tr><td><strong>16:45 \u2013 17:05<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA SUPORTIVNO I PALIJATIVNO LIJE\u010cENJE ONKOLO\u0160KIH BOLESNIKA <\/strong><br><strong>(SECTION SUPPORTIVE AND PALLIATIVE TREATMENT OF ONCOLOGY PATIENTS)<\/strong><\/td><\/tr><tr><td><\/td><td><strong>Maurizio Muscarritoli, Borislav Belev<\/strong><br>Pronto protokol (Pronto protocol)<\/td><\/tr><tr><td>17:05 \u2013 17:20<\/td><td><strong>PAUZA ZA KAVU I RAZGLEDAVANJE <em>POSTERA <\/em><\/strong><br><strong>(COFFEE BREAK AND POSTER VIEWING)<\/strong><\/td><\/tr><tr><td>17:20 &#8211; 18:05<\/td><td><strong>SATELITSKI SIMPOZIJ ROCHE <\/strong><br><strong>(SATELLITE SYMPOSIUM ROCHE)<\/strong><\/td><\/tr><tr><td><\/td><td>Put prema boljim ishodima lije\u010denja<br>(The path towards better treatment outcomes)<br><br>Moderator (Moderator): <strong>Stjepko Ple\u0161tina<\/strong><br>Predava\u010di (Lecturers): <strong>Toma\u0161 <strong>B\u00fcchler<\/strong>, Natalija Dedi\u0107 Plaveti\u0107, Nina Dabeli\u0107<\/strong><\/td><\/tr><tr><td>18:05 \u2013 18:50<\/td><td><strong>SATELITSKI SIMPOZIJ AstraZeneca<\/strong><br><strong>(SATELLITE SYMPOSIUM AstraZeneca<\/strong>)<\/td><\/tr><tr><td><\/td><td>Precizna onkologija: Sudbina Pan-Tumor koncepta <br>(Precision Oncology: Destiny of Pan-Tumour concept)<br><br>Moderator (Moderator):&nbsp;<strong>Snje\u017eana Tomi\u0107<\/strong><br><br><strong>Stjepko Ple\u0161tina, Eduard Vrdoljak, Natalija Dedi\u0107 Plaveti\u0107, Marko Jakopovi\u0107<\/strong><\/td><\/tr><tr><td>18:50 \u2013 19:55<\/td><td><strong>SATELITSKI SIMPOZIJ BMS<\/strong><br><strong>(SATELLITE SYMPOSIUM BMS)<\/strong><\/td><\/tr><tr><td><\/td><td>Razmjena iskustva lije\u010denja terapijom temeljenom na nivolumabu razli\u010ditih vrsta tumora i stadija bolesti <br>Sharing experience of Nivolumab-based treatment across multiple tumor types and disease stages<br><br>Moderator (Moderator): <strong>Stjepko Ple\u0161tina<\/strong><\/td><\/tr><tr><td>18:50 \u2013 19:00<\/td><td><strong>Stjepko Ple\u0161tina<\/strong><br>Uvod (Introduction)<\/td><\/tr><tr><td>19:00 \u2013 19:15<\/td><td><strong>Davorin Herceg<\/strong><br>Iskustvo u lije\u010denju melanoma <br>(Experience in melanoma)<\/td><\/tr><tr><td>19:15 \u2013 19:30<\/td><td><strong>Marko Jakopovi\u0107<\/strong><br>Iskustvo u lije\u010denju torakalnih tumora (MPM, NSCLC)<br>(Experience in thoracic indications (MPM, NSCLC))<\/td><\/tr><tr><td>19:30 \u2013 19:45<\/td><td><strong>Marija Gamulin<\/strong><br>Iskustvo u lije\u010denju raka bubrega<br>(Experience in RCC)<\/td><\/tr><tr><td>19:45 \u2013 19:55<\/td><td>Rasprava (Discussion)<\/td><\/tr><tr><td><strong>20:00 \u2013 21:00<\/strong><\/td><td><strong>DOMJENAK DOBRODO\u0160LICE <\/strong><br>(<strong>WELCOME RECEPTION)<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-tab gutena-tab-block gutena-tab-block-f9a848-d1 inactive\" data-tab=\"2\">\n<h2 class=\"wp-block-heading has-medium-font-size\"><\/h2>\n\n\n\n<figure class=\"wp-block-flexible-table-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td style=\"width:160px;background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong><strong>DVORANA A (HALL A<\/strong><\/strong><\/strong>)<\/td><\/tr><tr><td><strong>08:00 \u2013 09:00<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA TUMORI S\u017dS, GLAVE I VRATA <\/strong><br><strong>(CNS, HEAD&amp;NECK SESSION)<\/strong><\/td><\/tr><tr><td style=\"width:160px\"><\/td><td>Moderatori (Moderators)<strong>: Vesna Bi\u0161of, Ana Mi\u0161ir Krpan, Zoran Raku\u0161i\u0107, Marija Skoblar, Majana So\u010de, Ljubica Vazdar<\/strong><\/td><\/tr><tr><td style=\"width:160px\">08:00 \u2013 08:15<\/td><td><strong>Ljubica Vazdar<\/strong><br>Novosti s ASCO i ESMO kongresa <br>(News from the ASCO and ESMO congresses)<\/td><\/tr><tr><td>08:15 \u2013 08:30<\/td><td><strong>Marija Skoblar<\/strong> <strong>Vidmar<\/strong><br>Leptomeningealna karcinomatoza: dijagnosti\u010dki i terapijski izazov<br>(Leptomeningeal carcinomatosis: a diagnostic and therapeutic challenge)<\/td><\/tr><tr><td>08:30 \u2013 08:45<\/td><td><strong>Ana Mi\u0161ir Krpan<\/strong><br>Profilakti\u010dko zra\u010denje mozga: pro et contra<br>(Prophylactic brain irradiation: pro et contra)<\/td><\/tr><tr><td>08:45 \u2013 09:00<\/td><td><strong>Marin Prpi\u0107<\/strong><br>Primjena imunoterapije u nemetastatskom planocelularnom raku glave i vrata <br>(Application of immunotherapy in non-metastatic squamous cell cancer of the head and neck)<\/td><\/tr><tr><td>09:00 \u2013 09:20<\/td><td><strong>SATELITSKI SIMPOZIJ EWOPHARMA <\/strong>&nbsp;<br><strong>(SATELLITE SYMPOSIUM<\/strong> <strong>EWOPHARMA<\/strong>)<\/td><\/tr><tr><td><\/td><td>Uloga lenvatiniba u lije\u010denju progresivnog karcinoma \u0161titnja\u010de refraktornog na radioaktivni jod <br>(The role of lenvatinib in the treatment of progressive differentiated thyroid carcinoma, refractory to radioactive iodine)<br><br><strong>Borislav Belev<\/strong><\/td><\/tr><tr><td>09:20 \u2013 09:50<\/td><td><strong><strong>SATELITSKI SIMPOZIJ MSD<\/strong><\/strong><br><strong>(SATELLITE SYMPOSIUM MSD)<\/strong><\/td><\/tr><tr><td><\/td><td>Pembrolizumab u lije\u010denju metastatskog ili rekurentnog neresektabilnog HNSCC:&nbsp;Personalizirani&nbsp;pristup lije\u010denju!<br>Pembrolizumab in the treatment of metastatic or recurrent unresectable HNSCC: A personalized approach!<br>&nbsp;<br>Predava\u010d \/ Speaker: <strong>Vesna Bi\u0161of<\/strong><\/td><\/tr><tr><td style=\"background-color:#7bdcb5\"><\/td><td style=\"background-color:#7bdcb5\"><strong><strong>DVORANA B (HALL B<\/strong>)<\/strong><\/td><\/tr><tr><td>09:00 \u2013 09:30<\/td><td><strong>SATELITSKI SIMPOZIJ AstraZeneca<\/strong><br><strong>(SATELLITE SYMPOSIUM AstraZeneca<\/strong>)<\/td><\/tr><tr><td><\/td><td>ADAURA u klini\u010dkoj praksi <br>(ADAURA in clinical practice)<\/td><\/tr><tr><td>09:30 \u2013 10:00<\/td><td><strong>SATELITSKI SIMPOZIJ ROCHE<\/strong><br><strong>(SATELLITE SYMPOSIUM ROCHE)<\/strong><\/td><\/tr><tr><td><\/td><td>Mijenjamo zajedno ishode lije\u010denja bolesnika s ranim rakom plu\u0107a<br>(Changing together the clinical outcomes in early lung cancer)<br><br>Moderator: <strong>Miroslav Samar\u017eija<\/strong><br>Predava\u010di: <strong>Sanja Ple\u0161tina, Marko Jakopovi\u0107<\/strong><\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong><strong>DVORANA A (HALL A<\/strong><\/strong><\/strong>)<\/td><\/tr><tr><td><strong>10:00 \u2013 11:00<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA<\/strong> <strong>TUMORI PLU\u0106A <\/strong><br><strong>(LUNG TUMORS SECTION)<\/strong><\/td><\/tr><tr><td><\/td><td>Moderatori (Moderators): <strong>Marko Jakopovi\u0107, Sanja Ple\u0161tina, Miroslav Samar\u017eija, Dragan Trivanovi\u0107<\/strong><br><br>Panelisti (Panelists): <strong>Maja Hrabak Paar, Goran Mad\u017earac, Tihana Pavi\u0107, Snje\u017eana Tomi\u0107<\/strong><\/td><\/tr><tr><td>10:00 \u2013 10:30<\/td><td><strong>Marko Jakopovi\u0107<\/strong>, <strong>Lidija Ljubi\u010di\u0107<\/strong><br>Rak plu\u0107a \u2013 Je li vrijeme za perioperativno lije\u010denje raka plu\u0107a? <br>(Lung cancer &#8211; Is it time for perioperative treatment of lung cancer?)<\/td><\/tr><tr><td>10:30 \u2013 11:00<\/td><td><strong>Dragan Trivanovi\u0107<\/strong>, I<strong>va Sko\u010dili\u0107<\/strong><br>Lokalno uznapredovali rak plu\u0107a <br>(Locally advanced lung cancer)<\/td><\/tr><tr><td><strong>11:00 &#8211; 11:30<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA<\/strong> <strong>SUPORTIVNO I PALIJATIVNO LIJE\u010cENJE ONKOLO\u0160KIH BOLESNIKA <\/strong><br><strong>(SECTION SUPPORTIVE AND PALLIATIVE TREATMENT OF ONCOLOGICAL PATIENTS)<\/strong><\/td><\/tr><tr><td><\/td><td>Invazivni postupci u palijativnoj medicini &#8211; kada i kome? <br>(Invasive procedures in palliative medicine &#8211; when and for whom?)<\/td><\/tr><tr><td>11:00 \u2013 11:15<\/td><td><strong>Sonja Badovinac<\/strong><br>Mjesto interventne pulmologije u palijativnom zbrinjavanju onkolo\u0161kih bolesnika<br>(The place of interventional pulmonology in the palliative care of cancer patients)<\/td><\/tr><tr><td>11:15 \u2013 11:30<\/td><td><strong>Dra\u017een Perkov<\/strong><br>Uloga stentiranja u palijativnom zbrinjavanju onkolo\u0161kih bolesnika sa sindromom gornje \u0161uplje vene <br>(The role of stenting in the palliative care of cancer patients with superior vena cava syndrome)<\/td><\/tr><tr><td>11:30 \u2013 11:45<\/td><td><strong>PAUZA ZA KAVU I RAZGLEDAVANJE POSTERA<br>(COFFEE BREAK AND POSTER VIEWING)<\/strong><\/td><\/tr><tr><td><strong>11:45 \u2013 12:15<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA<\/strong> <strong>TUMORI PLU\u0106A <\/strong><br><strong>(LUNG TUMORS SECTION)<\/strong><\/td><\/tr><tr><td><\/td><td>Moderatori (Moderators): <strong>Marko Jakopovi\u0107, Sanja Ple\u0161tina, Miroslav Samar\u017eija, Dragan Trivanovi\u0107<\/strong><br><br>Panelisti (Panelists): <strong>Maja Hrabak Paar, Goran Mad\u017earac, Tihana Pavi\u0107, Snje\u017eana Tomi\u0107<\/strong><\/td><\/tr><tr><td><\/td><td><strong>Sanja Ple\u0161tina, Ana Ba\u010deli\u0107 Gabelica<\/strong><br>Novosti u lije\u010denju metastatskog raka plu\u0107a nemalih stanica <br>(Innovations in the treatment of metastatic non-small cell lung cancer)<\/td><\/tr><tr><td>12:15 \u2013 13:00<\/td><td><strong>SATELITSKI SIMPOZIJ MSD<\/strong><br><strong>(SATELLITE SYMPOSIUM MSD)<\/strong><\/td><\/tr><tr><td><\/td><td>Pembrolizumab u lije\u010denju ranog i metastatskog raka plu\u0107a \u2013 bez obzira na PD-L1 ekspresiju Va\u0161ih bolesnika<br>Pembrolizumab in early and metastatic lung cancer treatment \u2013 regardless of &nbsp;PD-L1 expression<br>&nbsp;<br>Panelisti \/ Panelists: <strong>Marko Jakopovi\u0107, Sanja Ple\u0161tina<\/strong><\/td><\/tr><tr><td>13:00 \u2013 13:30<\/td><td><strong>SATELITSKI SIMPOZIJ PFIZER<\/strong><br><strong>(SATELLITE SYMPOSIUM<\/strong> <strong>PFIZER<\/strong>)<\/td><\/tr><tr><td><\/td><td>Optimalno prvolinijsko lije\u010denje kod ALK+ NSCLC bolesnika<br>(Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer)<br><br><strong>Miroslav Samar\u017eija<\/strong><br>\u010cimbenici koji odre\u0111uju terapijski izbor u 1L <br>(Factors that affecting therapeutic choice in 1L)<br><br><strong>Sanja Ple\u0161tina<\/strong><br>Ima li razlike izme\u0111u ALK inhibitora u 1L? <br>(Are there any differences among ALK inhibitors in 1L)<br><br><strong>Marko Jakopovi\u0107<\/strong><br>Za\u0161to primijeniti lorlatinib u 1L <br>(Why to choose lorlatinib in 1L)<\/td><\/tr><tr><td>13:30 \u2013 14:00<\/td><td><strong>SATELITSKI SIMPOZIJ AMGEN<\/strong><br><strong>(SATELLITE SYMPOSIUM<\/strong> <strong>AMGEN)<\/strong><\/td><\/tr><tr><td><\/td><td>U\u010dinkovitost sotorasiba u lije\u010denju KRAS G12C-mutiranog NSCLC \u2013 novi podaci&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>(New evidence on efficacy of sotorasib in the treatment of KRAS G12C mutated NSCLC)<br><br>Moderator (Moderator): <strong>Marko Jakopovi\u0107<\/strong>&nbsp;<\/td><\/tr><tr><td>13:30 \u2013 13:45<\/td><td><strong>Sanja Ple\u0161tina<\/strong><br>Sotorasib u lije\u010denju bolesnika s KRAS G12C mutiranim NSCLC i presadnicama u mozgu <br>Sotorasib in Patients With KRAS G12C-Mutated NSCLC and Brain Metastases<\/td><\/tr><tr><td>13:45 \u2013 13:55<\/td><td><strong>Dra\u017eena Srdi\u0107<\/strong><br>Prikaz bolesnika lije\u010denog sotorasibom u KPB Jordanovac <br>(A patient treated with sotorasib &#8211; case presentation)<\/td><\/tr><tr><td>13:55 \u2013 14:00<\/td><td>Rasprava (Q&amp;A session)<br><strong>Marko Jakopovi\u0107, Sanja Ple\u0161tina, Dra\u017eena Srdi\u0107<\/strong><\/td><\/tr><tr><td style=\"background-color:#7bdcb5\"><\/td><td style=\"background-color:#7bdcb5\"><strong><strong>DVORANA B (HALL B<\/strong>) <\/strong><\/td><\/tr><tr><td>12:30 \u2013 13:00<\/td><td><strong>SATELITSKI SIMPOZIJ AMGEN<\/strong><br><strong>(SATELLITE SYMPOSIUM AMGEN)<\/strong><\/td><\/tr><tr><td><\/td><td>PARADIGM studija &#8211; ju\u010der, danas, sutra &#8211; \u0161to smo sve saznali o panitumumabu?&nbsp; <br><br>Moderator (Moderator): <strong>Stjepko Ple\u0161tina<\/strong><\/td><\/tr><tr><td>12:30 \u2013 12:40<\/td><td><strong>Stjepko Ple\u0161tina<\/strong><br>PARADIGM studija &#8211; potvrda na\u0161ih iskustava u lije\u010denju metastatskog kolorektalnog carcinoma &#8211; uvod&nbsp;<\/td><\/tr><tr><td>12:40 \u2013 12:50<\/td><td><strong>Borislav Belev<\/strong><br>PARADIGM studija &#8211; \u0161to nam je sve pokazao panitumumab<\/td><\/tr><tr><td>12:50 \u2013 13:00<\/td><td><strong>Domina Kekez<\/strong><br>Nove smjernice za lije\u010denje metastatskog kolorektalnog karcinoma i \u0161to to zna\u010di za na\u0161e pacijente?<\/td><\/tr><tr><td>13:00 \u2013 13:30<\/td><td><strong>SATELITSKI SIMPOZIJ ROCHE<\/strong><br><strong>(SATELLITE SYMPOSIUM ROCHE)<\/strong><\/td><\/tr><tr><td><\/td><td>IMbrave &#8211; hrabrost na svakom koraku u lije\u010denju HCC-a&nbsp;&nbsp;<br>(IMbrave \u2013 courage at every step of the HCC patient&#8217;s journey)<br><br>Moderator (Moderator): <strong>Stjepko Ple\u0161tina<\/strong><br><br>Predava\u010di (Lecturers):&nbsp;<strong>Tajana Filipec Kani\u017eaj, Juraj Prejac, Hrvoje Silovski<\/strong><\/td><\/tr><tr><td>13:30 \u2013 14:00<\/td><td><strong>SATELITSKI SIMPOZIJ SERVIER<\/strong><br><strong>(SATELLITE SYMPOSIUM SERVIER)<\/strong><\/td><\/tr><tr><td><\/td><td>Nove terapijske opcije za pobolj\u0161anje rezultata lije\u010denja bolesnika s tumorima probavnog sustava<br>(New treatment strategies in GI tumors to improve patient outcomes)<\/td><\/tr><tr><td>13:30 \u2013 13:45<\/td><td><strong>Stjepko Ple\u0161tina<\/strong><br>Produljenje kontinuuma skrbi u bolesnika s mCRC<br>(Further extending the continuum of care in mCRC)<\/td><\/tr><tr><td>13:45 \u2013 14:00<\/td><td><strong>Eduard Vrdoljak<\/strong><br>Promjena terapijskog pristupa u lije\u010denju kolangiokarcinoma: Koja je uloga molekularnog testiranja?<br>(Changing treatment landscape in cholangiocarcinoma: What is the role of molecular testing?)<\/td><\/tr><tr><td><strong>14:00 \u2013 15:00<\/strong><\/td><td><strong>RU\u010cAK (LUNCH)<\/strong><\/td><\/tr><tr><td style=\"background-color:#7bdcb5\"><\/td><td style=\"background-color:#7bdcb5\"><strong><strong><strong>DVORANA B (HALL B<\/strong>) <\/strong><\/strong><\/td><\/tr><tr><td>15:00 \u2013 15:30<\/td><td><strong>SATELITSKI SIMPOZIJ JANSSEN<\/strong><br><strong>(SATELLITE SYMPOSIUM JANSSEN)<\/strong><\/td><\/tr><tr><td><\/td><td>Novosti u lije\u010denju NSCLC-a s EGFR egzon20ins mutacijom \u2013 ciljana terapija<br>(Expanding horizons for management of NSCLC with EGFR exon 20ins &#8211; targeted therapy)&nbsp;<br><br><strong>Marko Jakopovi\u0107, Sanja Ple\u0161tina, Marijo Boban<\/strong><\/td><\/tr><tr><td>15:30 \u2013 16:00<\/td><td><strong>SATELITSKI SIMPOZIJ A&amp;B d.o.o (Biocartis)<\/strong><br><strong>(SATELLITE SYMPOSIUM <strong>A&amp;B d.o.o (Biocartis)<\/strong><\/strong>)<\/td><\/tr><tr><td><\/td><td>Molekularna dijagnostika raka pluca: NGS, Idylla GeneFusion test ili oboje<br>Lung cancer molecular diagnostics: NGS, Idylla Genefusion Assay or both<br><br>Moderator: <strong>Snje\u017eana Tomi\u0107<\/strong><br>Panelisti: <strong>Lovorka Batelja-Vuleti\u0107, Jasna Radi\u0107, Snje\u017eana Tomi\u0107<\/strong><\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong><strong>DVORANA A (HALL A<\/strong><\/strong><\/strong>)<\/td><\/tr><tr><td>15:00 \u2013 15:30<\/td><td><strong>SATELITSKI SIMPOZIJ AstraZeneca<\/strong><br><strong>(SATELLITE SYMPOSIUM AstraZeneca<\/strong>)<\/td><\/tr><tr><td><\/td><td>Nove perspektive u lije\u010denju GI tumora: \u0160to nam otkrivaju studije TOPAZ i HIMALAYA <br>(New perspectives in the treatment of GI tumors: What TOPAZ and HIMALAYA studies reveal)<br><br><strong>Juraj Prejac<\/strong><\/td><\/tr><tr><td>15:30 \u2013 16:00<\/td><td><strong>SATELITSKI SIMPOZIJ GENESISPHARMA<\/strong><br><strong>(SATELLITE SYMPOSIUM<\/strong> <strong>GENESISPHARMA<\/strong>)<\/td><\/tr><tr><td><\/td><td>Pemazyre (pemigatinib) u lije\u010denju odraslih osoba s lokalno uznapredovalim ili metastatskim kolangiokarcinomom<br>(Pemazyre (pemigatinib) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma)<br>&nbsp;<br><strong>Stjepko Ple\u0161tina, Juraj Prejac<\/strong><\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong>DVORANA A (HALL A<\/strong>)<\/td><\/tr><tr><td><strong>16:00 \u2013 18:00<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA PROBAVNI TUMORI <\/strong><br><strong>(DIGESTIVE TUMORS SECTION)<\/strong><\/td><\/tr><tr><td><\/td><td>Moderatori (Moderators): <strong>Borislav Belev, Renata Dobrila Dintinjana, Stjepko Ple\u0161tina, Juraj Prejac<\/strong><\/td><\/tr><tr><td>16:00 \u2013 16:15<\/td><td><strong>Marin Gol\u010di\u0107<\/strong><br>Personalizirana terapija u GI-tumorima \u2013 koliko smo napredovali? (Personalized therapy in GI tumors \u2013 how far have we progressed?)<\/td><\/tr><tr><td>16:15 \u2013 16:45<\/td><td><strong>Dora Tomek Hamzi\u0107<\/strong><br>Lokalno uznapredovali karcinom gu\u0161tera\u010de <br>(Locally advanced pancreatic cancer)<br>Prikaz slu\u010daja (Case presentation)<br><br>Panel rasprava (Panel discussion): <strong>Dra\u017een Perkov, Nik\u0161a Librenjak, Igor Petrovi\u0107, Majana So\u010de<\/strong><\/td><\/tr><tr><td>16:45 \u2013 17:00<\/td><td><strong>PAUZA ZA KAVU I RAZGLEDAVANJE POSTERA<br>(COFFEE BREAK AND POSTER VIEWING)<\/strong><\/td><\/tr><tr><td>17:00 \u2013 17:30<\/td><td><strong>Domina Kekez<\/strong><br>HCC \u2013 koji je optimalni koncept lije\u010denja? (HCC \u2013 what is the optimal treatment concept?)<br>Prikaz slu\u010daja (Case presentation)<br><br>Panel rasprava (Panel discussion): <strong>Anna Mrzljak, Igor Petrovi\u0107, Juraj Prejac, Dra\u017een Perkov<\/strong><\/td><\/tr><tr><td>17:30 -17:50<\/td><td><strong>Josip Joachim Grah<\/strong><br>Uloga stereotaksijske radioterapije u lijecenju primarnih tumora jetre <br>(The role of stereotaxic radiotherapy in the treatment of primary liver tumors)<\/td><\/tr><tr><td>17:50 &#8211; 18:10<\/td><td><strong>Majana So\u010de<\/strong><br>Znamo li \u0161to je optimalno lije\u010denje raka rektuma? <br>(Do we know what is the optimal treatment for rectal cancer?)<\/td><\/tr><tr><td>18:10 \u2013 18:30<\/td><td><strong>Dragan Trivanovi\u0107<\/strong><br>Novosti sa AACR, koji nam novi lijekovi dolaze u budu\u0107nosti? (News from AACR, what new drugs are coming our way in the future?)<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-tab gutena-tab-block gutena-tab-block-c641e1-f4 inactive\" data-tab=\"3\">\n<h2 class=\"wp-block-heading has-medium-font-size\"><\/h2>\n\n\n\n<figure class=\"wp-block-flexible-table-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td style=\"width:160px;background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong>DVORANA A (HALL A<\/strong><\/strong>)<\/td><\/tr><tr><td style=\"width:160px\"><strong>08:00 \u2013 09:00<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA MELANOM, MEZENHIMALNI I RIJETKI TUMORI <\/strong><br><strong>(MELANOMA, SARCOMA AND RARE TUMORS SECTION<\/strong>)<\/td><\/tr><tr><td style=\"width:160px\"><strong>08:00 \u2013 08:30<\/strong><\/td><td><strong>MELANOM \/ MELANOMA<\/strong><br><br>Panelisti (Panelists): <strong>Jasmina Mari\u0107 Brozi\u0107, Nina Dabeli\u0107, Davorin Herceg, Luka Simeti\u0107, Da\u0161ka \u0160tulhofer-Buzina<\/strong><\/td><\/tr><tr><td>08:00 \u2013 08:15<\/td><td><strong>Davorin Herceg<\/strong><br>Europska i regionalna suradnja u registru za melanom \u2013 EUMelaReg&nbsp;<br>(EUMelaReg- European Melanoma Registry\u201c- european and regional collaboration)<\/td><\/tr><tr><td>08:15 \u2013 08:25&nbsp;&nbsp;<\/td><td><strong>Kre\u0161imir Bla\u017ei\u010devi\u0107<\/strong><br>Ishodi lije\u010denja metastatskog melanoma u Hrvatskoj na temelju podataka iz EUMelareg-a <br>(Treatment outcomes for patients with metastatic melanoma in Croatia \u2013 EUMelaReg data analysis)<\/td><\/tr><tr><td>08:25 \u2013 08:30<\/td><td>Diskusija (Discussion)&nbsp;<\/td><\/tr><tr><td><strong>08:30 \u2013 09:00<\/strong><\/td><td><strong>SARKOMI \/ SARCOMA<\/strong><br><br>Panelisti (Panelists): <strong>Ivan Boha\u010dek, Snje\u017eana Dotli\u0107,&nbsp;Davorin Herceg, Luka Simeti\u0107, Marko \u0160imunovi\u0107<\/strong><\/td><\/tr><tr><td>08:30 \u2013 08:40<\/td><td><strong>Tatjana Ladenhauser<\/strong><br>Iskustva u lije\u010denju lokaliziranog osteosarkoma &nbsp;<br>(Single center experience- localized osteosarcoma treatment)<\/td><\/tr><tr><td>08:40 \u2013 08:50<\/td><td><strong>Kata Me\u0111ugorac<\/strong><br>Prikaz slu\u010daja\/case presentation<strong>:<\/strong> <br>Neoadjuvantna kemoterapija kod sarkoma- multidisciplinarni pristup <br>(Neoadjuvant chemotherapy for sarcoma \u2013 multidisciplinary approach)<\/td><\/tr><tr><td>08:50 \u2013 09:00<\/td><td>Diskusija (Discussion)<\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong><strong>DVORANA A (HALL A<\/strong><\/strong>)<\/strong><\/td><\/tr><tr><td>09:00 \u2013 09:30<\/td><td><strong>SATELITSKI SIMPOZIJ MEDISON PHARMA<\/strong><br><strong>(SATELLITE SYMPOSIUM MEDISON PHARMA)<\/strong><\/td><\/tr><tr><td><\/td><td>Metastatski melanom uvee: \u0161to trebamo znati <br><em>(Metastatic melanoma of the uvea: what we need to know<\/em>)<br><br>Moderator:&nbsp; <strong>Stjepko Ple\u0161tina<\/strong><br><br><strong>Nina Dabeli\u0107<\/strong><br>Melanom uvee i mogu\u0107nosti lije\u010denja <br>(Uveal melanoma and treatment options)<br><br><strong>Luka Simeti\u0107<\/strong><br>Na\u0161a iskustva<br><em>(Our experiences)<\/em><\/td><\/tr><tr><td>09:30 \u2013 10:15<\/td><td><strong>SATELITSKI SIMPOZIJ MSD<\/strong><br><strong><strong>(SATELLITE SYMPOSIUM <\/strong>MSD)<\/strong><\/td><\/tr><tr><td><\/td><td>Uz lijek Keytruda\u00ae mijenjamo ishode lije\u010denja bolesnika s melanomom<br>With Keytruda\u00ae, we are changing treatment outcomes for melanoma patients<br>&nbsp;<br>Panelisti \/ Panelists: <strong>Davorin Herceg, Luka Simeti\u0107<\/strong><\/td><\/tr><tr><td style=\"background-color:#7bdcb5\"><\/td><td style=\"background-color:#7bdcb5\"><strong>DVORANA B (HALL B<\/strong>)<\/td><\/tr><tr><td>09:00 \u2013 09:30<\/td><td><strong>SATELITSKI SIMPOZIJ PFIZER<\/strong><br><strong><strong>(SATELLITE SYMPOSIU<\/strong>M PFIZER)<\/strong><\/td><\/tr><tr><td><\/td><td>Put pacijenta s metastatskim rakom dojke &#8211; 5 godina iskustva sa palbociklibom<br>(Mapping the mBC patient journey &#8211; 5 years experience with Palbociclib)<br><br><strong>Ljubica Vazdar, Mario Nalbani, Anu\u0161ka Budisavljevi\u0107<\/strong><\/td><\/tr><tr><td>09:30 \u2013 10:15<\/td><td><strong>ZNANSTVENI SIMPOZIJ NOVARTIS<\/strong> <br><strong>(SCIENTIFIC SYMPOSIUM<\/strong> <strong>NOVARTIS)<\/strong><\/td><\/tr><tr><td><\/td><td>Rani rak dojke <br>(Early breast cancer)<\/td><\/tr><tr><td>09:30 \u2013 09:35<\/td><td><strong>Stjepko Ple\u0161tina<\/strong><br>Uvod <br>(Introduction)<\/td><\/tr><tr><td>09:35 \u2013 09:55<\/td><td><strong>Dejan Juri\u0107<\/strong><br>CDK4\/6i u ranom karcinomu dojke <br>(CDK4\/6i in early breast cancer)<\/td><\/tr><tr><td>09:55 \u2013 10:15<\/td><td>Rasprava\/Discussion<br><strong>Natalija Dedi\u0107 Plaveti\u0107, Dejan Juri\u0107, Stjepko Ple\u0161tina, Eduard Vrdoljak<\/strong><\/td><\/tr><tr><td><strong>10:15 \u2013 10:30<\/strong><\/td><td><strong>PAUZA ZA KAVU I RAZGLEDAVANJE POSTERA <\/strong><br><strong>(COFFEE BREAK AND POSTER VIEWING<\/strong>)<\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong>DVORANA A (HALL A<\/strong><\/strong>)<\/td><\/tr><tr><td><strong>10:30 \u2013 12:30<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA RAK DOJKE <\/strong><br><strong>(BREAST CANCER SECTION<\/strong>)<\/td><\/tr><tr><td><\/td><td>Uklju\u010divanje novih terapijskih opcija u lije\u010denju raka dojke &#8211; izme\u0111u \u017eelja i stvarnosti\u201d <br>(Implementation of novel therapeutic options in breast cancer treatment &#8211; between wishful thinking and reality)<br><br>Moderatori (Moderators): <strong>Natalija Dedi\u0107 Plaveti\u0107, Anu\u0161ka Budisavljevi\u0107<\/strong><br><br>Panelisti (Panelists): <strong>Dejan Juri\u0107, Simona Bor\u0161tnar, Marija Ban, Tajana Silovski, Renata Kelemeni\u0107-Dra\u017ein, Marijana Jazvi\u0107<\/strong><\/td><\/tr><tr><td>10:30 \u2013 11:00<\/td><td><strong>Mario Nalbani<\/strong><br>Pregled novosti u lije\u010denu raka dojke; ASCO, ESMO, SABCS i SGBCC (Overview of news in breast cancer treatment; ASCO, ESMO, SABCS i SGBCC)<\/td><\/tr><tr><td>11:00 \u2013 11:25<\/td><td><strong>Karla Zekuli\u0107, Anamarija Kova\u010d Pei\u0107<\/strong><br>Trostruko negativan rak dojke, prikaz slu\u010daja i rasprava <br>(Triple negative breast cancer, case report and panel discussion)<\/td><\/tr><tr><td>11:25 \u2013 11:50<\/td><td><strong>Ivana Matani\u0107, Nikolina Lonjak<\/strong><br>HR+ pozitivan rak dojke, pr\u00edkaz slu\u010daja i rasprava <br>(HR+ breast cancer, case report and panel discussion)<\/td><\/tr><tr><td>11:50 \u2013 12:15<\/td><td><strong>Jurica Vrbanec, Marina Popovi\u0107<\/strong><br>HER2 pozitivan rak dojke, prikaz slu\u010daja i rasprava <br>(HER2+ breast cancer, case report and panel discussion)<\/td><\/tr><tr><td>12:15 \u2013 12:30<\/td><td>Zavr\u0161na rije\u010d i zaklju\u010dci panela <br>(Session wrap up and panel conclusions)<\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong>DVORANA A (HALL A<\/strong><\/strong>)<\/td><\/tr><tr><td>12:30 \u2013 13:00<\/td><td><strong>SATELITSKI SIMPOZIJ ELI LILLY<\/strong><br><strong>(SATELLITE SYMPOSIUM ELI LILLY)<\/strong><\/td><\/tr><tr><td><\/td><td>Kad je rizik visok dajte joj nadu, i vi\u0161e!<br>(When the risk is high give her hope, and more!)<br><br>Moderator (Moderator): <strong>Stjepko Ple\u0161tina<\/strong><\/td><\/tr><tr><td>12:30 \u2013 12:35<\/td><td>Uvod moderatora<br>(Moderator\u2019s introduction)<\/td><\/tr><tr><td>12:35 \u2013 12:45<\/td><td><strong>Paula Podolski<\/strong><br>Uloga abemacikliba u dana\u0161njoj klini\u010dkoj praksi <br>(The role of abemaciclib in today&#8217;s clinical practice)<\/td><\/tr><tr><td>12:45 \u2013 12:55<\/td><td><strong>Mario Nalbani<\/strong><br>monarchE \u2013 Odr\u017eana u\u010dinkovitost abemacikliba <br>(monarchE \u2013 Sustained efficacy of abemaciclib)<\/td><\/tr><tr><td>12:55 \u2013 13:00<\/td><td>Zaklju\u010dak moderatora <br>(Moderator\u2019s Conclusion)<\/td><\/tr><tr><td>13:00 \u2013 13:45<\/td><td><strong>SATELITSKI SIMPOZIJ AstraZeneca<\/strong><br><strong>(SATELLITE SYMPOSIUM AstraZeneca)<\/strong><\/td><\/tr><tr><td><\/td><td>PARPe diem \u2013 Lynparza u lije\u010denju raka jajnika, dojke i prostate <br>(PARPe diem \u2013 Lynparza in the treatment of ovarian, breast and prostate cancer)<br><br>Moderator (Moderator): <strong>Tihana Boraska Jelavi\u0107<\/strong><br><br><strong>Erik \u0160kof, Tajana Silovski, Tomislav Omr\u010den, Ivan Milas&nbsp;&nbsp;<\/strong><\/td><\/tr><tr><td>13:45 \u2013 14:05<\/td><td><strong>SATELITSKI SIMPOZIJ MEDICOPHARMACIA<\/strong><br><strong>(SATELLITE SYMPOSIUM<\/strong> <strong>MEDICOPHARMACIA) <\/strong><\/td><\/tr><tr><td><\/td><td>Trodelvy u lije\u010denju metastatskog TNBC &#8211; prikaz slu\u010daja<br>(Trodelvy in the treatment of metastatic TNBC &#8211; case report)<br><br><strong>Anu\u0161ka Budisavljevi\u0107<\/strong><\/td><\/tr><tr><td>14:05 \u2013 15.00<\/td><td><strong>RU\u010cAK (LUNCH<\/strong>)<\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong>DVORANA A (HALL A<\/strong>)<\/td><\/tr><tr><td><strong>15:00 \u2013 16:00<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA MLADIH ONKOLOGA <\/strong><br><strong>(SECTION OF YOUNG ONCOLOGISTS)<\/strong><\/td><\/tr><tr><td><\/td><td>&#8220;Survivorship&#8221; onkolo\u0161kih bolesnika <br>(Survivorship of oncology patients)<\/td><\/tr><tr><td>15:00 \u2013 15:15<\/td><td><strong>Iva Nikles<\/strong><br>\u0160to je uop\u0107e \u201esurvivorship\u201c i za\u0161to je va\u017ean? <br>(What is survivorship anyway and why is it important?)<\/td><\/tr><tr><td>15:15 -15:30<\/td><td><strong>Ivana Kukec<\/strong><br>Psiho-socio-ekonomski aspekti onkolo\u0161kih bolesnika <br>(Psycho-socio-economic aspects of oncology patients)<\/td><\/tr><tr><td>15:30 \u2013 16:00<\/td><td>Panel rasprava na prakti\u010dnom primjeru bolesnice s rakom dojke <br>(Panel discussion on the practical example of a patient with breast cancer)<br><br>Voditelj panela (Panel leader): <strong>Martina Mladinovi\u0107<\/strong><br>Panelisti (Panelists): <strong>Hrvoje Vinter, Ivona Poljak, Marina Popovi\u0107, Iva Nikles, Mario Nalbani<\/strong><\/td><\/tr><tr><td><strong>16:00 \u2013 17:00<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA GINEKOLO\u0160KIH TUMORA <\/strong><br><strong>(SECTION OF GYNECOLOGICAL TUMORS)<\/strong><\/td><\/tr><tr><td><\/td><td>Moderator (Moderator): <strong>Vi\u0161nja Matkovi\u0107<\/strong><br><br>Panelisti (Panelists): <strong>Marija Milkovi\u0107 Peri\u0161a, Tihana Boraska Jelavi\u0107, Josip Kuhari\u0107<\/strong><\/td><\/tr><tr><td>16:00 \u2013 16:15<\/td><td><strong>Mihaela Trajbar<\/strong><br>Terapija odr\u017eavanja u prvoj liniji lije\u010denja epitelnog raka jajnika visokog stupnja nediferenciranosti \u2013 PARP inhibitori kao monoterapija ili u kombinaciji sa bevacizumabom <br>(Maintenance therapy in the first line of treatment of high grade epithelial ovarian cancer \u2013 PARP inhibitors monotherapy or in combination with bevacizumab)<\/td><\/tr><tr><td>16:15 \u2013 16:30<\/td><td><strong>Marija Milkovi\u0107 Peri\u0161a<\/strong><br>Molekularni biomarkeri u karcinomu endometrija \u2013 osvrt patologa <br>(New molecular biomarkers in endometrial cancer \u2013 view of a pathologist)<\/td><\/tr><tr><td>16:30 \u2013 16:45<\/td><td><strong>Ida \u010cepuli\u0107 Maravi\u0107<\/strong><br>Lije\u010denje metastatskog karcinoma endometrija \u2013 novosti i prostor za napredak <br>(Treatment of metastatic endometrial cancer \u2013 news and possibilities for improvement)<\/td><\/tr><tr><td>16:45 \u2013 17:00<\/td><td><strong>Tihana Boraska Jelavi\u0107<\/strong><br>Lije\u010denje metastatskog karcinoma vrata maternice \u2013 uloga imunoterapije (News in the treatment of metastatic cervical cancer \u2013 the role of immunotherapy)<\/td><\/tr><tr><td>17:00 \u2013 17:15<\/td><td><strong>PAUZA ZA KAVU I RAZGLEDAVANJE POSTERA <\/strong><br><strong>(COFFEE BREAK AND POSTER VIEWING)<\/strong><\/td><\/tr><tr><td>17:15 \u2013 17:45<\/td><td><strong>SATELITSKI SIMPOZIJ NOVARTIS<\/strong><br><strong>(SATELLITE SYMPOSIUM NOVARTIS)<\/strong><\/td><\/tr><tr><td><\/td><td>Kisqali (ribociklib) \u2013 \u017divjeti du\u017ee uz odr\u017eanu ili pobolj\u0161anu kvalitetu \u017eivota<br>(Kisqali (ribociclib) \u2013 Living longer with maintained or improved quality of life)<br><br><strong>Tajana Silovski, Marina Popovi\u0107<\/strong><\/td><\/tr><tr><td><strong>17:45 \u2013 18:30<\/strong><\/td><td><strong>SKUP\u0160TINA HDIO (\u010dlanovi HDIO) <\/strong><br><strong>HDIO ASSEMBLY (HDIO members)<\/strong><\/td><\/tr><tr><td style=\"background-color:#7bdcb5\"><\/td><td style=\"background-color:#7bdcb5\"><strong>DVORANA B (HALL B<\/strong>)<\/td><\/tr><tr><td><strong>14:00 \u2013 18:00&nbsp;&nbsp;&nbsp;<\/strong><\/td><td style=\"color:#f78da7\"><strong><strong><strong>SEKCIJA ZA PACIJENTE <\/strong><\/strong><\/strong><br><strong><strong><strong>(SECTION FOR PATIENTS)<\/strong><\/strong><\/strong><\/td><\/tr><tr><td>14:00 \u2013 14:05<\/td><td><strong>Stjepko Ple\u0161tina i predstavnica pacijenata<\/strong><br>Otvaranje Sekcije za pacijente<br>(Section Opening)<\/td><\/tr><tr><td>14:05 &#8211; 14:30<\/td><td><strong>Eduard Vrdoljak<\/strong><br>Za\u0161to Onkologija?<br>(Why Oncology?)<\/td><\/tr><tr><td>14:30 &#8211; 14:45<\/td><td><strong>Natalija Dedi\u0107 Plaveti\u0107<\/strong><br>Precizna medicina i personalizirano lije\u010denje&nbsp;<br>(Precision medicine and personalized treatment)<\/td><\/tr><tr><td>14:45 &#8211; 15:00<\/td><td><strong>Vi\u0161nja Matkovi\u0107<\/strong><br>Lije\u010denje bolesnica s rakom jajnika<br>(Treatment of patients with ovarian cancer)<\/td><\/tr><tr><td>15:00 &#8211; 15:15<\/td><td><strong>Ana Ba\u010deli\u0107 Gabelica<\/strong><br>Suportivno i palijativno lije\u010denje onkolo\u0161kih bolesnika<br>(Cancer patients supportive and palliative treatment)<\/td><\/tr><tr><td>15:15 &#8211; 15:30<\/td><td>Diskusija (Discussion)<\/td><\/tr><tr><td>15:30 \u2013 16:00<\/td><td><strong>PAUZA ZA KAVU <br>(COFFEE BREAK)<\/strong><\/td><\/tr><tr><td>16:00 &#8211; 16:15<\/td><td><strong>Sanja Ple\u0161tina<\/strong><br>Predstavljanje ESMO vodi\u010da za bolesnike &#8220;\u0160to je rak plu\u0107a nemalih stanica&#8221;<br>(Presentation of the ESMO guide for patients &#8220;What is non-small cell lung cancer&#8221;) <\/td><\/tr><tr><td>16:15 &#8211; 16:30<\/td><td><strong>Paula Podolski<\/strong><br>Lije\u010denje bolesnica s rakom dojke kroz vrijeme<br>(Treatment of breast cancer patients over time)<\/td><\/tr><tr><td>16:30 &#8211; 16:45<\/td><td><strong>Anu\u0161ka Budisavljevi\u0107<\/strong><br>Kvaliteta \u017eivota onkolo\u0161kih bolesnika<br>(Quality of life of oncology patients)<\/td><\/tr><tr><td>16:45 &#8211; 17:00<\/td><td><strong>Marina Popovi\u0107<\/strong><br>Benefiti psihoonkolo\u0161ke pomo\u0107i pacijentima iz perspektive onkologa i \u201esurvivorship\u201c<br>(Benefits of psycho-oncology assistance to patients from the perspective of oncologists and &#8220;survivorship&#8221;)<\/td><\/tr><tr><td>17:00 &#8211; 17:30<\/td><td>\u201ePosition paper\u201c udruga i Inovativne farmaceutske inicijative<br>\u201cAssociations\u2019 and Innovative pharmaceutical initiative\u2019s<br>\u201cPosition paper\u201d<br><br>Moderator\/Moderator: <strong>Ljiljana Vukota<\/strong><br>Panelisti\/Panelists: <br>predstavnici udruga, Inovativne farmaceutske inicijative i onkologije <br>(representatives of associations, innovative pharmaceutical initiative and oncology) <\/td><\/tr><tr><td>17:30 &#8211; 17:35<\/td><td>Zatvaranje programa Sekcije<br>(Section Closing)<\/td><\/tr><tr><td style=\"background-color:#abb8c3\"><strong>20.00<\/strong><\/td><td style=\"background-color:#abb8c3\"><strong>KONGRESNA VE\u010cERA <\/strong><br><strong>(CONGRESS DINNER)<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-gutena-tab gutena-tab-block gutena-tab-block-df6927-4b inactive\" data-tab=\"4\">\n<h2 class=\"wp-block-heading has-medium-font-size\"><\/h2>\n\n\n\n<figure class=\"wp-block-flexible-table-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td style=\"width:160px;background-color:#abb8c3\"><\/td><td style=\"background-color:#abb8c3\"><strong><strong>DVORANA A (HALL A<\/strong><\/strong>)<\/td><\/tr><tr><td style=\"width:160px\">08:30 \u2013 09:15<\/td><td><strong>SATELITSKI SIMPOZIJ ASTELLAS<\/strong><br><strong>(SATELLITE SYMPOSIUM ASTELLAS)<\/strong><\/td><\/tr><tr><td><\/td><td>Astellas iskustvo i inovacija: putovanje dugo 10 godina i po\u010detak novog pravca u onkologiji<br>(Astellas experience and innovation: a 10-year journey and the beginning of a new direction in oncology)<\/td><\/tr><tr><td>08:30 \u2013 09:00<\/td><td>\u0160to nam nosi Xtandi u svakodnevnom radu pri dugotrajnom lije\u010denju bolesnika s uznapredovalim hormonski osjetljivim rakom prostate<br>(What Xtandi brings to us in daily work during the long-term treatment of patients with advanced hormone-sensitive prostate cancer)<br><br>Panel diskusija (Panel discussion):&nbsp;<strong><strong>Marija Gamulin, Zrna Antunac Golubi\u0107, Jasmin Bekti\u0107<\/strong><\/strong><\/td><\/tr><tr><td>09:00 &#8211; 09:15<\/td><td>\u0160to nam donosi Padcev u lije\u010denju lokalno uznapredovalog i metastatskog urotelnog karcinoma?&nbsp;&nbsp;<br>(What does Padcev bring to us in the treatment of locally advanced and metastatic urothelial carcinoma)<br><br><strong>Tomislav Omr\u010den&nbsp;&nbsp;&nbsp;<\/strong><\/td><\/tr><tr><td style=\"width:160px\">09:15 &#8211; 10:00<\/td><td><strong>SATELITSKI SIMPOZIJ MERCK<\/strong><br><strong>(SATELLITE SYMPOSIUM MERCK)<\/strong><\/td><\/tr><tr><td><\/td><td>Odr\u017eavanje s lijekom Bavencio\u00ae u 1. liniji mUC<br>(Maintenance with Bavencio\u00ae in 1. line mUC)<br><br><strong>Milena Gnjidi\u0107<\/strong><br>Javelin Bladder 100<br>(Javelin Bladder 100)<br><br><strong>Jure Murgi\u0107<\/strong><br>Iskustva u primjeni lijeka Bavencio\u00ae<br>Odgovori na klju\u010dna pitanja klini\u010dara kroz raspravu<br>(Experiences in the use of Bavencio\u00ae<br>Answers to clinicians&#8217; key questions through discussion)<\/td><\/tr><tr><td>10:00 \u2013 10:30<\/td><td><strong>SATELITSKI SIMPOZIJ JANSSEN<\/strong><br><strong>(SATELLITE SYMPOSIUM JANSSEN)<\/strong><\/td><\/tr><tr><td><\/td><td>Za\u0161to izabrati lijek Erleada u lije\u010denju raka prostate? <br>(Why choose Erleada for prostate cancer treatment?)<br><br><strong>Milena Gnjidi\u0107, Renata Kelemeni\u0107 Dra\u017ein, Nikola Bulj<\/strong><\/td><\/tr><tr><td>10:30 \u2013 11:00<\/td><td><strong>SATELITSKI SIMPOZIJ NOVARTIS<\/strong><br><strong>(SATELLITE SYMPOSIUM NOVARTIS)<\/strong><\/td><\/tr><tr><td><\/td><td>Iskorak u novu dimenziju u lije\u010denju mCRPC-a<br>(Stepping out into a new dimension in mCRPC treatment)<br><br><strong>Marija Gamulin<\/strong><\/td><\/tr><tr><td><strong>11:00 \u2013 11:15<\/strong><\/td><td><strong>PAUZA ZA KAVU I RAZGLED POSTERA <\/strong><br><strong>(COFFEE BREAK AND POSTER VIEW)<\/strong><\/td><\/tr><tr><td><strong>11:15 \u2013 12:45<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA UROGENITALNI TUMORI <\/strong><br><strong>(UROGENITAL TUMORS SECTION)<\/strong><\/td><\/tr><tr><td><\/td><td>Moderatori (Moderators): <strong>Borislav Belev, Milena Gnjidi\u0107<\/strong><\/td><\/tr><tr><td>11:15 \u2013 11:45&nbsp;<\/td><td><strong>Maja Bau\u010di\u0107, Ivan Vi\u010di\u0107<\/strong><br>Prikaz slu\u010daja (Case preseentation):<br>Uloga nuklearne medicine u dijagnostici karcinoma prostate: PSMA PET-CT (The role of nuclear medicine in the diagnosis of prostate cancer: PSMA PET-CT)<br><br><strong>Marija Gamulin, Milena Gnjidi\u0107, Tvrtko Hudolin<\/strong><br>Panel rasprava (Panel discussion):<br>Primjena dijagnosti\u010dkih metoda nuklearne medicine u svakodnevnoj praksi (Application of diagnostic methods of nuclear medicine in everyday practice)<\/td><\/tr><tr><td>11:45 \u2013 12:10<\/td><td>Metastatski hormon-osjetljivi karcinom prostate \u2013 kako odabrati ADT-partnera? <br>(Metastatic hormone-sensitive prostate cancer &#8211; how to choose an ADT partner?)<br><br><strong>Martina Mladinovi\u0107<\/strong> &#8211; prikaz slu\u010daja (case presentation)<br><br>Panel rasprava (Panel discussion): <strong>Vesna Bi\u0161of, Tomislav Omr\u010den, Tvrtko Hudolin, Mislav \u010conka\u0161, Lidija Koci\u0107<\/strong><\/td><\/tr><tr><td>12:10 \u2013 12:35<\/td><td><strong>Zrna Antunac Golubi\u0107<\/strong><br>Novosti u lije\u010denju urotelnog karcinoma <br>(News in the treatment of urothelial cancer)<br><br>Panel rasprava (Panel discussion):<br><strong>Mirko Bakula, Zrna Antunac Golubi\u0107, Stela Bulimba\u0161i\u0107, Marijana Jazvi\u0107<\/strong><\/td><\/tr><tr><td>12:35 \u2013 12:45<\/td><td><strong>Anamarija Kova\u010d Pei\u0107<\/strong><br>Izazovi i iskustva u lije\u010denju uroonkolo\u0161kih bolesnika u neklini\u010dkim centrima (Challenges and experiences in the treatment of uro-oncology patients in non-clinical centers)<\/td><\/tr><tr><td><strong>12:45 \u2013 13:15<\/strong><\/td><td style=\"color:#0693e3\"><strong>SEKCIJA POTPORNE I PALIJATIVNE MEDICINE <\/strong><br><strong>(SUPPORTIVE AND PALLIATIVE TREATMENT SECTION)<\/strong><\/td><\/tr><tr><td><\/td><td>Razgovori o skrbi na kraju \u017eivota <br>(Conversations about end-of-life care)<br><br>Moderator: <strong>Sanja Ple\u0161tina<\/strong><\/td><\/tr><tr><td>12:45 \u2013 12:55<\/td><td><strong>Ana Borove\u010dki<\/strong><br>\u0160to zna\u010di dobra smrt za Hrvate? <br>(What does a good death mean for Croats?)<\/td><\/tr><tr><td>12:55 \u2013 13:00<\/td><td><strong>Ivana Kukec<\/strong><br>Prikaz rezultata interne ankete&nbsp;<br>(Presentation of the results of the internal survey)<\/td><\/tr><tr><td>13:00 \u2013 13:15<\/td><td>Panel rasprava (Panel discussion):<br>(pro et contra) &#8211; Da li umrijeti kod ku\u0107e ili u ustanovi? <br>(Should you die at home or in an institution?)<br><br>Panelisti (Panelists)<strong>:&nbsp; Sanja Ple\u0161tina, Ana Borove\u010dki, Ivana Kukec, Antonija Salamun, Ana Kotarski, Ru\u017eica Valent, Ivona Poljak<\/strong><\/td><\/tr><tr><td>13:15 &#8211; 14:00<\/td><td><strong>BEST OF HDIO &#8211; Progla\u0161enje najboljih radova i zatvaranje kongresa (Announcement of the best papers and closing of the Congress<\/strong>)<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Finalni program kongresa preuzmite ovdje<\/p>","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-137","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/pages\/137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/comments?post=137"}],"version-history":[{"count":93,"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/pages\/137\/revisions"}],"predecessor-version":[{"id":391,"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/pages\/137\/revisions\/391"}],"wp:attachment":[{"href":"https:\/\/web.penta-pco.com\/hdio-2023\/en\/wp-json\/wp\/v2\/media?parent=137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}